Vivelle-Dot vs. Bijuve

See how Vivelle-Dot and Bijuve compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Vivelle-Dot is a twice-weekly estrogen-only patch, while Bijuve is a once-daily capsule that already combines estrogen and progesterone in each dose.

  • Women with a uterus using Vivelle-Dot need a separate progestin prescription, but Bijuve already includes progesterone to protect the uterine lining.

  • Both carry boxed warnings for blood clots, stroke, dementia, and breast cancer, so either choice calls for a personal risk discussion with a doctor.

Vivelle-Dot vs. Bijuve Drug Summary

Vivelle-Dot

Vivelle-Dot is an estrogen-only hormone patch that delivers estradiol through the skin. It treats moderate to severe hot flashes and vaginal dryness from menopause, and can also treat low estrogen from ovarian failure or prevent bone loss after menopause. The patch is changed twice a week and comes in five strengths so a clinician can adjust the estrogen dose.

Bijuve

Bijuve is a combination hormone capsule that pairs estradiol with micronized progesterone in a single dose. It treats moderate to severe hot flashes from menopause in women who still have a uterus, where the built-in progesterone protects the uterine lining from unopposed estrogen. It is taken as one capsule by mouth once a day.

Vivelle-Dot vs. Bijuve Side Effects

Vivelle-Dot

Most common
Respiratory infection (up to 17%)
Sinusitis (up to 13%)
Sinus headache (up to 11%)
Back pain (up to 10%)

Bijuve

Most common
Breast tenderness (up to 10.4%)
Headache (up to 3.4%)
Vaginal bleeding (up to 3.4%)
Vaginal discharge (up to 3.4%)

Vivelle-Dot vs. Bijuve Dosage

Vivelle-Dot

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 0.0375 mg/day patch At the start
Maximum dose 0.025-0.1 mg/day patch If needed
Dose changes 2 increases As tolerated

Bijuve

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 0.5 mg/100 mg once daily At the start
Maximum dose 0.5 mg/100 mg once daily Same as starting
Dose changes None Fixed dose

Vivelle-Dot vs. Bijuve Indications

Vivelle-Dot

Vivelle-Dot is FDA-approved for moderate to severe hot flashes and vaginal dryness caused by menopause. It also treats low estrogen levels from ovarian failure or hypogonadism, and can prevent bone loss after menopause. Because it delivers estrogen alone, a separate progestin is usually needed for women who still have a uterus.

  • Moderate to severe hot flashes from menopause

  • Vaginal dryness and irritation from menopause

  • Low estrogen from ovarian failure or hypogonadism

  • Prevention of postmenopausal osteoporosis

Bijuve

Bijuve is FDA-approved specifically for moderate to severe hot flashes caused by menopause in women who still have a uterus. The progesterone in each capsule protects the uterine lining from the estrogen, so it is not approved for women without a uterus. It is also not approved to prevent heart disease, stroke, or dementia.

  • Moderate to severe hot flashes from menopause

  • For women who still have a uterus only

  • Progesterone included to protect the uterus

  • Not approved for women without a uterus

Vivelle-Dot vs. Bijuve Pros and Cons

Vivelle-Dot

Vivelle-Dot offers flexible dosing across five patch strengths and is one of the few estrogen products also approved to prevent bone loss. As an estrogen-only product, it needs to be paired with a separate progestin for anyone with a uterus, and generic pricing is far below the brand.

Pros

  • Five dose strengths allow fine-tuned titration

  • Also approved to prevent postmenopausal osteoporosis

  • Transdermal delivery may carry lower clot risk than oral estrogen

Cons

  • Requires a separate progestin prescription for women with a uterus

  • Patch can cause skin redness or irritation at the site

  • Brand-name supply has been inconsistent amid 2026 shortages

  • Must be changed and site-rotated twice a week

Bijuve

Bijuve simplifies hormone therapy for women with a uterus into one daily capsule instead of two separate prescriptions. Because it is taken orally, it carries the higher clotting risk associated with oral versus transdermal estrogen, and it is not an option for women without a uterus. There is no generic version, and its list price runs well above generic estradiol patch pricing.

Pros

  • One capsule combines estrogen and progesterone, no second prescription

  • No patch or skin site care required

  • Only FDA-approved bioidentical estradiol and progesterone combo capsule

Cons

  • Oral estrogen carries higher clot risk than transdermal options

  • Not approved for women without a uterus

  • No generic version, costing roughly $257 to $351 a month

  • Not approved for preventing osteoporosis

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.